Last reviewed · How we verify
Almonertinib plus carboplatin and pemetrexed
Almonertinib plus carboplatin and pemetrexed is a EGFR tyrosine kinase inhibitor (almonertinib) + platinum-based chemotherapy + antifolate Small molecule drug developed by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. It is currently in Phase 3 development for Advanced or metastatic non-small cell lung cancer with EGFR mutations. Also known as: Aleime, Ameile.
Almonertinib inhibits EGFR tyrosine kinase while carboplatin and pemetrexed provide platinum-based chemotherapy and antimetabolite activity, respectively, to target non-small cell lung cancer.
Almonertinib inhibits EGFR tyrosine kinase while carboplatin and pemetrexed provide platinum-based chemotherapy and antimetabolite activity, respectively, to target non-small cell lung cancer. Used for Advanced or metastatic non-small cell lung cancer with EGFR mutations.
At a glance
| Generic name | Almonertinib plus carboplatin and pemetrexed |
|---|---|
| Also known as | Aleime, Ameile |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
| Drug class | EGFR tyrosine kinase inhibitor (almonertinib) + platinum-based chemotherapy + antifolate |
| Target | EGFR (epidermal growth factor receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Almonertinib is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to mutant EGFR, particularly effective against common mutations and some resistant variants. Carboplatin is a platinum agent that causes DNA crosslinking and cell death, while pemetrexed is an antifolate that inhibits multiple enzymes in nucleotide synthesis. The combination leverages targeted therapy with almonertinib alongside conventional chemotherapy for enhanced efficacy.
Approved indications
- Advanced or metastatic non-small cell lung cancer with EGFR mutations
Common side effects
- Nausea and vomiting
- Myelosuppression
- Rash
- Diarrhea
- Fatigue
Key clinical trials
- Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations (PHASE3)
- A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer (PHASE3)
- A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy (PHASE3)
- A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation (PHASE3)
- Almonertinib With Chemotherapy in mEGFR NSCLC (PHASE2)
- Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer (PHASE2)
- Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Almonertinib plus carboplatin and pemetrexed CI brief — competitive landscape report
- Almonertinib plus carboplatin and pemetrexed updates RSS · CI watch RSS
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences portfolio CI
Frequently asked questions about Almonertinib plus carboplatin and pemetrexed
What is Almonertinib plus carboplatin and pemetrexed?
How does Almonertinib plus carboplatin and pemetrexed work?
What is Almonertinib plus carboplatin and pemetrexed used for?
Who makes Almonertinib plus carboplatin and pemetrexed?
Is Almonertinib plus carboplatin and pemetrexed also known as anything else?
What drug class is Almonertinib plus carboplatin and pemetrexed in?
What development phase is Almonertinib plus carboplatin and pemetrexed in?
What are the side effects of Almonertinib plus carboplatin and pemetrexed?
What does Almonertinib plus carboplatin and pemetrexed target?
Related
- Drug class: All EGFR tyrosine kinase inhibitor (almonertinib) + platinum-based chemotherapy + antifolate drugs
- Target: All drugs targeting EGFR (epidermal growth factor receptor)
- Manufacturer: Cancer Institute and Hospital, Chinese Academy of Medical Sciences — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Advanced or metastatic non-small cell lung cancer with EGFR mutations
- Also known as: Aleime, Ameile
- Compare: Almonertinib plus carboplatin and pemetrexed vs similar drugs
- Pricing: Almonertinib plus carboplatin and pemetrexed cost, discount & access